OR9

(6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol

Created:2020-08-24
Last modified:  2021-02-24

Help

Find related ligands:

Chemical Details

Formal Charge0
Atom Count37
Chiral Atom Count1
Bond Count40
Aromatic Bond Count12
2D diagram of OR9
Toggle HydrogenToggle Labels

Chemical Component Summary

Name(6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
Systematic Name (OpenEye OEToolkits)(6~{a}~{R})-6-methyl-5,6,6~{a},7-tetrahydro-4~{H}-dibenzo[de,g]quinoline-10,11-diol
FormulaC17 H17 N O2
Molecular Weight267.322
TypeNON-POLYMER

Chemical Descriptors

TypeProgramVersionDescriptor
SMILESACDLabs12.01C12Cc4ccc(c(c4c3c1c(CCN2C)ccc3)O)O
SMILESCACTVS3.385CN1CCc2cccc3c2[CH]1Cc4ccc(O)c(O)c34
SMILESOpenEye OEToolkits2.0.7CN1CCc2cccc-3c2C1Cc4c3c(c(cc4)O)O
Canonical SMILESCACTVS3.385 CN1CCc2cccc3c2[C@H]1Cc4ccc(O)c(O)c34
Canonical SMILESOpenEye OEToolkits2.0.7 CN1CCc2cccc-3c2[C@H]1Cc4c3c(c(cc4)O)O
InChIInChI1.03 InChI=1S/C17H17NO2/c1-18-8-7-10-3-2-4-12-15(10)13(18)9-11-5-6-14(19)17(20)16(11)12/h2-6,13,19-20H,7-9H2,1H3/t13-/m1/s1
InChIKeyInChI1.03 VMWNQDUVQKEIOC-CYBMUJFWSA-N

Drug Info: DrugBank

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
DrugBank IDDB00714 
NameApomorphine
Groups
  • investigational
  • approved
DescriptionApomorphine is a non-ergoline dopamine D2 agonist indicated to treat hypomobility associated with Parkinson's. It was first synthesized in 1845 and first used in Parkinson's disease in 1884.[A203618] Apomorphine has also been investigated as an emetic, a sedative, a treatment for alcoholism, and a treatment of other movement disorders.[A203597,A203618] Apomorphine was granted FDA approval on 20 April 2004.[L13919]
Synonyms
  • Apomorphin
  • (−)-10,11-dihydroxyaporphine
  • Apomorfina
  • (R)-5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol
  • (6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
Brand Names
  • Apokyn
  • Kynmobi
  • Movapo
  • Apomorphine Hydrocloride
IndicationApomorphine is indicated to treat acute, intermittent treatment of hypomobility, off episodes associated with advanced Parkinson's disease.[L13919,L13922]
Categories
  • Alkaloids
  • Anti-Parkinson Agents (Dopamine Agonist)
  • Anti-Parkinson Drugs
  • Antidepressive Agents
  • Aporphines
ATC-Code
  • G04BE07
  • N04BC07
CAS number58-00-4

Drug Targets

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
NameTarget SequencePharmacological ActionActions
D(4) dopamine receptorMGNRSTADADGLLAGRGPAAGASAGASAGLAGQGAAALVGGVLLIGAVLA...unknownagonist
D(2) dopamine receptorMDPLNLSWYDDDLERQNWSRPFNGSDGKADRPHYNYYATLLTLLIAVIVF...unknownagonist
D(3) dopamine receptorMASLSQLSGHLNYTCGAENSTGASQARPHAYYALSYCALILAIVFGNGLV...unknownagonist
D(1B) dopamine receptorMLPPGSNGTAYPGQFALYQQLAQGNAVGGSAGAPPLGPSQVVTACLLTLL...unknownagonist
D(1A) dopamine receptorMRTLNTSAMDGTGLVVERDFSVRILTACFLSLLILSTLLGNTLVCAAVIR...unknownagonist
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL53
PubChem 6005
ChEMBL CHEMBL53
ChEBI CHEBI:48538
CCDC/CSD FIKFIP